Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a…
Continue ReadingCDF CEO, Marilyn Geller, will present the celiac patient voice at the May 11 FDA Patient-Focused Drug Development meeting. Have your voice be heard. Complete the CDF Celiac PFDD Survey now.
Continue ReadingNew drugs on the research horizon could spare people with celiac the pain of accidentally eating pizza or pasta. Even with the best intentions, living gluten-free is much easier said than done. It was almost impossible to tell which packaged “gluten-free” foods lived up to their claims until late last year when the U.S. Food and Drug Administration (FDA) began enforcing gluten-free labeling guidelines. And it's hard to guarantee you won’t accidentally consume gluten at a restaurant or on an occasion, such as a well-meaning relative’s dinner party.
Continue ReadingOn March 30-31st, 2015, Celiac Disease Foundation Chief Executive Officer, Marilyn G. Geller, attended the FDA Public Workshop on Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT3) near Washington,…
Continue ReadingLast month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...